Wells Fargo raised the firm’s price target on Keros Therapeutics (KROS) to $28 from $11 and keeps an Overweight rating on the shares. The safety findings announced in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension, “basically zeroed expectations,” though cash plus pipeline is worth more than where the stock is right now, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target lowered to $47 from $100 at H.C. Wainwright
- BofA cuts Keros target to $33, says ‘story still intact’ despite ‘setback’
- Keros Therapeutics downgraded to Hold from Buy at TD Cowen
- Keros Therapeutics downgraded to Market Perform from Outperform at William Blair
- Keros Therapeutics downgraded to Neutral from Buy at BTIG